Category Archives: People

Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. market close on June 26, 2026, as part of the […]

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. […]

Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes

NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 […]

GuideAI Health Corp. to Begin Trading on Cboe Canada Under the Symbol “GDAI”

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) — GuideAI Health Corp. (“GuideAI” or the “Company“) (Cboe CA: GDAI) is pleased to report that the Company has received final approval to list its common shares (the “Shares”) on Cboe Canada Inc. (“Cboe Canada“). The Company anticipates that the Shares will begin trading at the market open on […]

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

– Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p<0.0001), the first and only statistically significant placebo-controlled arm span result reported for an achondroplasia trial at […]

TBoostExperts.com Announces Availability of 2026 Consumer Report on Testosterone Booster Supplements and Men’s Health Supplement Evaluation

New report provides an educational framework for reviewing testosterone booster supplements, ingredient transparency, supplement labels, consumer safety considerations, and responsible product research. NEW YORK,USA, June 27, 2026 (GLOBE NEWSWIRE) — TBoostExperts.com today announced the availability of its 2026 Consumer Research Report on testosterone booster supplements and men’s health supplement evaluation, a newly published educational resource […]

BurnTide Official Announces 2026 In Across The USA, UK, CA and AU Effective Formula Burn Tide Gummies For Weight Loss in Markets

Announcing BurnTide Gummies, a natural supplement designed to complement healthy weight loss. Learn how Burn Tide fits into a balanced diet, active lifestyle, and daily wellness routine. New York City, June 27, 2026 (GLOBE NEWSWIRE) — June 2026 — BurnTide today announced the launch of BurnTide Gummies, a new line of natural weight loss formula […]

COSLUS E40 Water Flosser Earns ADA Seal of Acceptance, Bringing Professional Oral Care Into Daily Routines

CITY OF INDUSTRY, CA, June 26, 2026 (GLOBE NEWSWIRE) — COSLUS, a global brand specializing in professional-grade oral care devices, today announced that its flagship ADA-Accepted water flosser, the COSLUS E40, has earned the American Dental Association (ADA) Seal of Acceptance. Three additional COSLUS products—C20, C50, and C51—have also earned the ADA Seal of Acceptance.The ADA […]

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and […]

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth […]